Guardant Health, NRG Oncology to validate use of MRD assay in colon cancer trial
The NRG-GI005 study will validate the clinical utility of Guardant Health’s molecular residual disease assay (Credit: Pixabay)
NS Medical Devices is using cookies
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X